Then, we established trastuzumab-resistant (HR) subclones of the two above-mentioned HER2+ BC cancer cell lines to investigate the therapeutically exploitable role of HDAC6 by using the specific inhibitor NexturastatA. Here, HDAC6 is linked to breast cancer.